Taros EVP Youri R. Mesmoudi was interviewed in the current Issue of CHEManager´s Section Chemistry & Life Sciences on “From Idea to Product – the principle of an extended workbench accelerates innovation in chemistry”
Read more
Due to current situation with the spread of the Sars-CoV-2 (“Coronavirus”) we want to share with you the latest information on how Taros Chemicals have prepared for both, the protection of our employees and partners’ health and the uninterrupted continuation of our chemistry and discovery services to our clients…
Ahead of Oxford Global’s R&D Series Drug Discovery Summit on 26-27 May 2019 in Berlin, Germany, Oxford Global spoke to Torsten Hoffmann of Taros Chemicals about his work in Pharmaceutical R&D and the opportunities and challenges in Drug Discovery…
I3-STM dealt with a new, tailor-made immunotherapeutic approach using small antibody mimetics synthesized for the therapy of triple-negative breast cancer (TNBC), which is still insufficiently treated with the classic methods. These drugs consist of components that stimulate the immune system and…
A research cooperation of the Paracelsus Medical University Salzburg and the Paris Lodron University Salzburg co-founded a „Transfer Center for Extracellular Vesicles – Theralytic Technologies“ (EV-TT) to conduct fundamental and…
Taros’ CEO invited to speak on the exclusive Podcast of the XPOMET© Medicinale in Berlin, 10 – 12 Oct 2019. In the light of Dimitrios presenation at the XPOMET© Medicinale, he was invited to give a pre-talk about his opinion on the transformation of the drug discovery process and his activities to contribute to that…
ZeCardio Therapeutics (ZeCardioTx), a pharma company focused on the discovery of cardiovascular drugs using the zebrafish model and a proprietary screening platform, ZeCardio®, selected Taros’ SVP Drug Discovery, Dr. Torsten Hoffmann, to join…
The European Lead Factory (ELF) secured a total project budget of EUR 36.5 million under the second framework of the Innovative Medicines Initiative (IMI). Over the next 5 years, 20 partners in 7 countries will push forward the transformation of potential drug targets to new medicines in…
Starting from a recently identified endogenous inhibitor of vascular calcifications, Taros Drug Discovery scientists will be working in close collaboration with the Lead Discovery Center (LDC) in Dortmund and the Institute for…
Over the next three years, Taros Chemicals will work closely with a consortium of eight partners from industry and academia (molecular biology and cellular metabolic physiology) in the search for new drugs to treat diabetes. Taros scientists will actively…
